Weight loss drugs may combat deadly disease

Recent studies indicate that GLP-1 receptor agonist drugs, such as Ozempic and Wegovy, may offer benefits beyond treating diabetes and obesity. They could also contribute to reducing the risk of, detecting recurrence of, and preventing breast cancer. These potential benefits are linked to decreases in body mass index and chronic inflammation, which in turn lower estrogen levels associated with tumor growth. Although current evidence is observational and does not definitively prove that these medications directly affect cancer cells, future studies are promising and awaiting results from well-controlled clinical trials to confirm these relationships. The expert explains that the use of GLP-1 may provide additional advantages for individuals who struggle to lose weight through traditional methods, especially postmenopausal women.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل